Compare BLTE & SPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLTE | SPR |
|---|---|---|
| Founded | 2018 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.3B |
| IPO Year | 2022 | 2006 |
| Metric | BLTE | SPR |
|---|---|---|
| Price | $148.92 | $39.64 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $149.00 | $38.63 |
| AVG Volume (30 Days) | 244.0K | ★ 2.5M |
| Earning Date | 11-10-2025 | 10-31-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,393,600,000.00 |
| Revenue This Year | N/A | $19.70 |
| Revenue Next Year | N/A | $16.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $49.00 | $27.00 |
| 52 Week High | $160.55 | $42.33 |
| Indicator | BLTE | SPR |
|---|---|---|
| Relative Strength Index (RSI) | 68.29 | 67.15 |
| Support Level | $140.07 | $35.80 |
| Resistance Level | $154.00 | $39.74 |
| Average True Range (ATR) | 12.43 | 0.95 |
| MACD | 0.74 | 0.57 |
| Stochastic Oscillator | 78.20 | 95.70 |
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Spirit AeroSystems manufactures aerostructures, particularly fuselages, cockpits, wing sections, engine pylons, and nacelles for commercial and military aircraft. The company was spun out of Boeing in 2005 to become the largest independent supplier of aerostructures for commercial aircraft. Boeing and Airbus are the firm's primary customers—Boeing represented roughly 60% and Airbus roughly 20% of revenue in recent years. The company is highly exposed to Boeing's beleaguered 737 program, which accounts for nearly half the company's revenue. The company plans to be acquired by and reintegrated into Boeing by the end of 2025.